Skip to main content
padlock icon - secure page this page is secure

Open Access Developing novel biomarkers to be used in the treatment of nausea and vomiting induced by chemotherapy treatment

Download Article:
 Download
(PDF 251.6 kb)
 
Dr Yuhki Sato is a researcher based in the Department of Clinical Pharmacy at Oita University, Japan. He and his team are working to develop novel biomarkers that can help treat nausea and vomiting associated with cancer chemotherapy. ‘We are dealing with side effects from anti-cancer drugs with existing drugs, but as for vomiting, there are no effective remedies, so patients are tolerating the present situation,’ Sato explains. As such, the team is looking into Kampo products, which tend to be extracts of herbal formulations. In particular, the researchers are exploring how Kampo products can affect the gastrointestinal tract. ‘A large number of ingredients will be included in one Kampo drug, each of which will have a particular kind of action. Sometimes the effect of an ingredient included is unknown. It is thought that Kampo drugs administered orally will show their efficacy through various changes occurring in the gastrointestinal tract,’ Sato states. In their 2014 study, ‘Changes in plasma gastrointestinal peptide levels after platinum-based chemotherapy in oesophageal cancer patients’, the researchers sought to assess plasma gastrointestinal peptide levels and their association with appetite during chemotherapy in patients with oesophageal cancer, as platinum-based chemotherapy is widely recognised to cause severe gastrointestinal disorders. The research involved measuring the plasma gastrointestinal peptide levels and platinum concentrations in five patients with oesophageal cancer who underwent platinum-based chemotherapy before and at day three, eight and 28 after chemotherapy, while appetite profile was evaluated by visual analogy scale (VAS). The researchers found that platinum-based chemotherapy significantly reduced plasma ghrelin and feeding activity. This led them to surmise that gastrointestinal peptide levels in plasma might be good indicators of the expression of the gastrointestinal disorders by platinum-based chemotherapy in oesophageal cancer patients.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: AFFECT THE GASTROINTESTINAL TRACT; EXTRACTS OF HERBAL FORMULATIONS; GASTROINTESTINAL DISORDERS; KAMPO PRODUCTS; NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY; NOVEL BIOMARKERS; OESOPHAGEAL CANCER PATIENTS; PLASMA GASTROINTESTINAL PEPTIDE LEVELS; PLASMA GHRELIN AND FEEDING ACTIVITY; PLATINUM-BASED CHEMOTHERAPY; SIDE EFFECTS FROM ANTI-CANCER DRUGS

Document Type: Research Article

Publication date: March 1, 2019

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more